Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Propionyl carnitine

Drug Profile

Propionyl carnitine

Alternative Names: Dromos; Levocarnitine proprionate; Levocarnitine proprionate hydrochloride; PLC; Propionyl-L-carnitine; Propionyl-L-carnitine HCl; Propionyl-L-carnitine hydrochloride; ST 261

Latest Information Update: 24 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sigma-tau SpA
  • Developer Lee's Pharmaceutical; sigma-tau SpA
  • Class Anti-ischaemics; Heart failure therapies; Ischaemic heart disorder therapies; Small molecules; Trimethyl ammonium compounds; Vascular disorder therapies; Vitamins
  • Mechanism of Action Free radical scavengers; Pyruvate dehydrogenase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Peripheral arterial occlusive disorders
  • Discontinued Angina pectoris; Heart failure; Kidney disorders; Myocardial ischaemia; Ulcerative colitis

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Peripheral-arterial-occlusive-disorders(In volunteers) in China (PO, Tablet)
  • 02 Apr 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Austria, France, Germany, Hungary, Latvia, Lithuania, Poland and Spain (NCT01567956)
  • 19 Mar 2012 sigma-tau plans a phase III trial for Ulcerative colitis in Belgium, Czech Republic, Israel, Italy, Netherlands, Romania, Russia and Slovakia (NCT01538251)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top